Skip to main content
Top
Published in: Medical Oncology 6/2014

01-06-2014 | Original Paper

Prognostic factors that govern localized synovial sarcoma: a single institution retrospective study on 51 patients

Authors: Sameer Yaser, Samer Salah, Marwa Al-Shatti, Areej Abu-Sheikha, Ahmad Shehadeh, Iyad Sultan, Ahmad Salem, Maher Sughayer, Shaymaa Al-Loh, Abdelatif Al-Mousa

Published in: Medical Oncology | Issue 6/2014

Login to get access

Abstract

Synovial sarcoma is a rare type of sarcoma with poor prognosis. Data on relevant prognostic factors are inconsistent. The objective of this study was to determine the independent prognostic factors that govern local recurrence, distant metastasis and overall survival. A retrospective analysis of 51 patients treated for localized synovial sarcoma at a single institution by a multidisciplinary/multimodality approach over a period of 12 years. Patients, tumor and treatment characteristics were collected including age, sex, tumor site, location, depth, size, status of margins, histology subtype and involvement of bone or lymph nodes. Type of surgery, adjuvant chemotherapy and radiotherapy were also examined. The endpoints analyzed were local recurrence-free survival (LRFS), metastasis-free survival (MFS) and overall survival (OS). Median age of patients was 26 years (range 3–64 years) with 73 % above the age of 20 year. All patients received surgery, 57 % received adjuvant radiotherapy and 45 % adjuvant chemotherapy. The median survival was 111 months, and 5-year OS was 73 %. Deep seatedness of the tumor was linked to OS as the only independent risk factor. Twelve patients had local recurrence, and the 5-year LRFS was 61 %. Multivariate analysis determined negative margins and adjuvant radiotherapy as independent predicting factors for LRFS. Five-year MFS was 48 %; multivariate analysis identified monophasic subtype and site other than lower extremity as the only independent factors associated with inferior MFS. The most important factors that govern LRFS and MFS are negative margins and adjuvant radiotherapy for LRFS and tumor histology and site for MFS, while deep seatedness of the tumor is the sole independent factor that governs OS.
Literature
1.
go back to reference Brennan MF SS, Maki RG, et al. Sarcomas of the soft tissues and bone. DeVita VT, Hellmann S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 2005;35:1584. Brennan MF SS, Maki RG, et al. Sarcomas of the soft tissues and bone. DeVita VT, Hellmann S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 2005;35:1584.
2.
go back to reference Levi F, La Vecchia C, Randimbison L, Te VC. Descriptive epidemiology of soft tissue sarcomas in Vaud, Switzerland. Eur J Cancer. 1999;35(12):1711–6.PubMedCrossRef Levi F, La Vecchia C, Randimbison L, Te VC. Descriptive epidemiology of soft tissue sarcomas in Vaud, Switzerland. Eur J Cancer. 1999;35(12):1711–6.PubMedCrossRef
3.
go back to reference Ross JA, Severson RK, Davis S, Brooks JJ. Trends in the incidence of soft tissue sarcomas in the United States from 1973 through 1987. Cancer. 1993;72(2):486–90.PubMedCrossRef Ross JA, Severson RK, Davis S, Brooks JJ. Trends in the incidence of soft tissue sarcomas in the United States from 1973 through 1987. Cancer. 1993;72(2):486–90.PubMedCrossRef
4.
go back to reference Rydholm A, Berg NO, Gullberg B, Thorngren KG, Persson BM. Epidemiology of soft-tissue sarcoma in the locomotor system. A retrospective population-based study of the inter-relationships between clinical and morphologic variables. Acta Pathol Microbiol Immunol Scand A Pathol. 1984;92(5):363–74. Rydholm A, Berg NO, Gullberg B, Thorngren KG, Persson BM. Epidemiology of soft-tissue sarcoma in the locomotor system. A retrospective population-based study of the inter-relationships between clinical and morphologic variables. Acta Pathol Microbiol Immunol Scand A Pathol. 1984;92(5):363–74.
5.
go back to reference Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–30. doi:10.1002/ijc.22239.PubMedCrossRef Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–30. doi:10.​1002/​ijc.​22239.PubMedCrossRef
6.
go back to reference Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT–SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62(1):135–40.PubMed Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT–SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62(1):135–40.PubMed
9.
go back to reference Rubin BP, Fletcher CD, Inwards C, Montag AG, Peabody T, Qualman SJ, et al. Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med. 2006;130(11):1616–29. doi:10.1043/1543-2165(2006)130[1616:PFTEOS]2.0.CO;2.PubMed Rubin BP, Fletcher CD, Inwards C, Montag AG, Peabody T, Qualman SJ, et al. Protocol for the examination of specimens from patients with soft tissue tumors of intermediate malignant potential, malignant soft tissue tumors, and benign/locally aggressive and malignant bone tumors. Arch Pathol Lab Med. 2006;130(11):1616–29. doi:10.​1043/​1543-2165(2006)130[1616:​PFTEOS]2.​0.​CO;2.PubMed
10.
go back to reference Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350–62.PubMed Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350–62.PubMed
11.
go back to reference Wright PH, Sim FH, Soule EH, Taylor WF. Synovial sarcoma. J Bone Joint Surg Am. 1982;64(1):112–22.PubMed Wright PH, Sim FH, Soule EH, Taylor WF. Synovial sarcoma. J Bone Joint Surg Am. 1982;64(1):112–22.PubMed
12.
go back to reference Pack GT, Ariel IM. Synovial sarcoma (malignant synovioma); a report of 60 cases. Surgery. 1950;28(6):1047–84.PubMed Pack GT, Ariel IM. Synovial sarcoma (malignant synovioma); a report of 60 cases. Surgery. 1950;28(6):1047–84.PubMed
13.
go back to reference el-Naggar AK, Ayala AG, Abdul-Karim FW, McLemore D, Ballance WW, Garnsey L, et al. Synovial sarcoma. A DNA flow cytometric study. Cancer. 1990;65(10):2295–300.PubMedCrossRef el-Naggar AK, Ayala AG, Abdul-Karim FW, McLemore D, Ballance WW, Garnsey L, et al. Synovial sarcoma. A DNA flow cytometric study. Cancer. 1990;65(10):2295–300.PubMedCrossRef
14.
go back to reference Oda Y, Hashimoto H, Tsuneyoshi M, Takeshita S. Survival in synovial sarcoma. A multivariate study of prognostic factors with special emphasis on the comparison between early death and long-term survival. Am J Surg Pathol. 1993;17(1):35–44.PubMedCrossRef Oda Y, Hashimoto H, Tsuneyoshi M, Takeshita S. Survival in synovial sarcoma. A multivariate study of prognostic factors with special emphasis on the comparison between early death and long-term survival. Am J Surg Pathol. 1993;17(1):35–44.PubMedCrossRef
15.
go back to reference Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101(3):627–34. doi:10.1002/cncr.20386.PubMedCrossRef Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101(3):627–34. doi:10.​1002/​cncr.​20386.PubMedCrossRef
16.
go back to reference Bergh P, Meis-Kindblom JM, Gherlinzoni F, Berlin O, Bacchini P, Bertoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999;85(12):2596–607.PubMedCrossRef Bergh P, Meis-Kindblom JM, Gherlinzoni F, Berlin O, Bacchini P, Bertoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999;85(12):2596–607.PubMedCrossRef
17.
go back to reference Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000;18(10):2087–94.PubMed Lewis JJ, Antonescu CR, Leung DH, Blumberg D, Healey JH, Woodruff JM, et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol. 2000;18(10):2087–94.PubMed
18.
go back to reference Spillane AJ, A’Hern R, Judson IR, Fisher C, Thomas JM. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000;18(22):3794–803.PubMed Spillane AJ, A’Hern R, Judson IR, Fisher C, Thomas JM. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000;18(22):3794–803.PubMed
19.
go back to reference Cagle LA, Mirra JM, Storm FK, Roe DJ, Eilber FR. Histologic features relating to prognosis in synovial sarcoma. Cancer. 1987;59(10):1810–4.PubMedCrossRef Cagle LA, Mirra JM, Storm FK, Roe DJ, Eilber FR. Histologic features relating to prognosis in synovial sarcoma. Cancer. 1987;59(10):1810–4.PubMedCrossRef
20.
go back to reference Trassard M, Le Doussal V, Hacene K, Terrier P, Ranchere D, Guillou L, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001;19(2):525–34.PubMed Trassard M, Le Doussal V, Hacene K, Terrier P, Ranchere D, Guillou L, et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol. 2001;19(2):525–34.PubMed
21.
go back to reference Hajdu SI, Shiu MH, Fortner JG. Tendosynovial sarcoma: a clinicopathological study of 136 cases. Cancer. 1977;39(3):1201–17.PubMedCrossRef Hajdu SI, Shiu MH, Fortner JG. Tendosynovial sarcoma: a clinicopathological study of 136 cases. Cancer. 1977;39(3):1201–17.PubMedCrossRef
23.
go back to reference Schmidt D, Thum P, Harms D, Treuner J. Synovial sarcoma in children and adolescents. A report from the Kiel Pediatric Tumor Registry. Cancer. 1991;67(6):1667–72.PubMedCrossRef Schmidt D, Thum P, Harms D, Treuner J. Synovial sarcoma in children and adolescents. A report from the Kiel Pediatric Tumor Registry. Cancer. 1991;67(6):1667–72.PubMedCrossRef
24.
go back to reference Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993;217(1):72–7.PubMedCentralPubMedCrossRef Fong Y, Coit DG, Woodruff JM, Brennan MF. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993;217(1):72–7.PubMedCentralPubMedCrossRef
25.
go back to reference Cadman NL, Soule EH, Kelly PJ. Synovial sarcoma; an analysis of 34 tumors. Cancer. 1965;18:613–27.PubMedCrossRef Cadman NL, Soule EH, Kelly PJ. Synovial sarcoma; an analysis of 34 tumors. Cancer. 1965;18:613–27.PubMedCrossRef
26.
go back to reference Oda Y, Hashimoto H, Takeshita S, Tsuneyoshi M. The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma. Cancer. 1993;72(2):478–85.PubMedCrossRef Oda Y, Hashimoto H, Takeshita S, Tsuneyoshi M. The prognostic value of immunohistochemical staining for proliferating cell nuclear antigen in synovial sarcoma. Cancer. 1993;72(2):478–85.PubMedCrossRef
27.
go back to reference Roth JA, Enzinger FM, Tannenbaum M. Synovial sarcoma of the neck: a followup study of 24 cases. Cancer. 1975;35(4):1243–53.PubMedCrossRef Roth JA, Enzinger FM, Tannenbaum M. Synovial sarcoma of the neck: a followup study of 24 cases. Cancer. 1975;35(4):1243–53.PubMedCrossRef
28.
go back to reference Singer S, Baldini EH, Demetri GD, Fletcher JA, Corson JM. Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol. 1996;14(4):1201–8.PubMed Singer S, Baldini EH, Demetri GD, Fletcher JA, Corson JM. Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol. 1996;14(4):1201–8.PubMed
29.
go back to reference Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679–89.PubMed Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679–89.PubMed
30.
go back to reference Mandard AM, Petiot JF, Marnay J, Mandard JC, Chasle J, de Ranieri E, et al. Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. Cancer. 1989;63(7):1437–51.PubMedCrossRef Mandard AM, Petiot JF, Marnay J, Mandard JC, Chasle J, de Ranieri E, et al. Prognostic factors in soft tissue sarcomas. A multivariate analysis of 109 cases. Cancer. 1989;63(7):1437–51.PubMedCrossRef
32.
go back to reference Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11(7):1269–75.PubMed Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11(7):1269–75.PubMed
33.
go back to reference Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma–reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12(6):1137–49.PubMed Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma–reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12(6):1137–49.PubMed
34.
go back to reference Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11(7):1276–85.PubMed Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11(7):1276–85.PubMed
35.
go back to reference Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.PubMed Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238–47.PubMed
36.
go back to reference Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30(8):850–6. doi:10.1200/JCO.2011.37.7218.PubMedCrossRef Gronchi A, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30(8):850–6. doi:10.​1200/​JCO.​2011.​37.​7218.PubMedCrossRef
37.
go back to reference Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC). The Cochrane database of systematic reviews. 2000(2):CD001419. doi:10.1002/14651858.CD001419. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC). The Cochrane database of systematic reviews. 2000(2):CD001419. doi:10.​1002/​14651858.​CD001419.
38.
go back to reference Bramwell VH. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J Clin Oncol. 2001;19(5):1235–7.PubMed Bramwell VH. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care? J Clin Oncol. 2001;19(5):1235–7.PubMed
Metadata
Title
Prognostic factors that govern localized synovial sarcoma: a single institution retrospective study on 51 patients
Authors
Sameer Yaser
Samer Salah
Marwa Al-Shatti
Areej Abu-Sheikha
Ahmad Shehadeh
Iyad Sultan
Ahmad Salem
Maher Sughayer
Shaymaa Al-Loh
Abdelatif Al-Mousa
Publication date
01-06-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 6/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0958-8

Other articles of this Issue 6/2014

Medical Oncology 6/2014 Go to the issue